Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.83 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.83 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.83 |
| ▸ | MEN1 | O00255 | 2/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.83 |
| ▸ | HPGD | P15428 | 2/20 | 0.83 |
| ▸ | TP53 | P04637 | 2/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.83 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | TUBB4A | P04350 | 5/20 | 0.54 |
| ▸ | TUBB | P07437 | 5/20 | 0.54 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 0.54 |
| ▸ | TUBA1B | P68363 | 5/20 | 0.54 |
| ▸ | TUBA4A | P68366 | 5/20 | 0.54 |
| ▸ | TUBB4B | P68371 | 5/20 | 0.54 |
| ▸ | TUBB3 | Q13509 | 5/20 | 0.54 |
| ▸ | TUBB2A | Q13885 | 5/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Albendazole SCHEMBL29409236 | 1.00 | LMNA (0.83) | LMNACYP1A2MAPK1SMN1; SMN2NPSR1 | |
| Albendazole SCHEMBL7969988 | 1.00 | LMNA (0.83) | LMNACYP1A2MAPK1SMN1; SMN2NPSR1 | |
| Albendazole SCHEMBL28958723 | 0.99 | LMNA (0.81) | LMNACYP1A2MAPK1SMN1; SMN2NPSR1 | |
| Albendazole SCHEMBL28582887 | 0.99 | LMNA (0.81) | LMNACYP1A2MAPK1SMN1; SMN2NPSR1 | |
| Albendazole SCHEMBL23038783 | 0.94 | LMNA (0.74) | LMNACYP1A2MAPK1SMN1; SMN2NPSR1 | |
| Albendazole SCHEMBL15553526 | 0.94 | LMNA (0.74) | LMNACYP1A2MAPK1SMN1; SMN2NPSR1 | |
| Albendazole SCHEMBL23038781 | 0.94 | LMNA (0.74) | LMNACYP1A2MAPK1SMN1; SMN2NPSR1 | |
| Albendazole SCHEMBL5944379 | 0.94 | LMNA (0.73) | LMNACYP1A2MAPK1SMN1; SMN2NPSR1 | |
| Albendazole SCHEMBL28470926 | 0.94 | LMNA (0.73) | LMNACYP1A2MAPK1SMN1; SMN2NPSR1 | |
| Albendazole SCHEMBL28325579 | 0.93 | LMNA (0.72) | LMNACYP1A2MAPK1SMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 19208 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122063071-A | Method for detecting albendazole crystal form content | 常州齐晖药业有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-122056906-A | Insect repellent composition and application thereof in yak breeding | 阿坝州农业科学研究院 | 2026-05-19 | — | — | CN | claimed |
| CN-122039076-A | Preparation method of 2-methyl sulfoxide pyrimidine derivative | 石河子大学 | 2026-05-15 | — | — | CN | claimed |
| CN-122055142-A | Improved pill design for administration to ruminants and uses thereof | 反刍动物生物科技有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-20260102373-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2026-04-16 | — | — | US | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| WO-2026044269-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING ALZHEIMER'S DISEASE AND OTHER | SAFWAT SHERIF (US) | 2026-02-26 | — | — | WO | claimed |
| US-20260048013-A1 | PHARMACEUTICAL FORMULATION WITH IMPROVED SOLUBILITY AND BIOAVAILABILITY | CONSEJO SUPERIOR INVESTIGACION (ES) | 2026-02-19 | — | — | US | claimed |
| EP-4680203-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | Prolevi Bio AB (SE) | 2026-01-21 | — | — | EP | claimed |
| US-20260000769-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2026-01-01 | — | — | US | claimed |
| EP-0060810-B1 | ANTHELMINTICS | CIBA-GEIGY AG (CH) | 1984-10-17 | — | — | EP | claimed |
| EP-0059074-B1 | ANTHELMINTIC COMPOSITION AND THE USE THEREOF | SANKYO COMPANY LIMITED (JP) | 1984-10-10 | — | — | EP | claimed |
| US-4468390-A | Anthelmintic composition and the use thereof | SANKYO COMPANY, LIMITED (JP) | 1984-08-28 | — | — | US | claimed |
| EP-0093497-A2 | Anthelmintic treatment | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1983-11-09 | — | — | EP | claimed |
| EP-0090368-A1 | Anthelmintic preparations | HOECHST UK LIMITED (GB) | 1983-10-05 | — | — | EP | claimed |
| EP-0032853-B1 | PROCESS AND DEVICE FOR BRAKING AN AIRCRAFT BY DEFINING OPTIMUM SLIP OF THE BRAKED WHEELS | AEROSPATIALE SOCIETE NATIONALE INDUSTRIELLE (FR) | 1983-08-24 | — | — | EP | claimed |
| EP-0059074-A1 | Anthelmintic composition and the use thereof | SANKYO COMPANY LIMITED (JP) | 1982-09-01 | — | — | EP | claimed |
| EP-0003951-A1 | Process for the preparation of 2-benzimidazolecarbamic acid esters | ETHYL CORPORATION (US) | 1979-09-19 | — | — | EP | claimed |
| US-4152522-A | FROM ORTHO-NITROANILINE | ETHYL CORPORATION (US) | 1979-05-01 | — | — | US | claimed |
| US-3956499-A | ANTHELMINTICS | SMITHKLINE CORPORATION (US) | 1976-05-11 | — | — | US | claimed |